ALCOR Scientific

ALCOR Scientific

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $11M

Overview

ALCOR Scientific has established itself as a specialized leader in the in-vitro diagnostics (IVD) market by re-engineering the century-old Erythrocyte Sedimentation Rate (ESR) test. Its flagship iSED product line utilizes novel photometric rheology technology to deliver results in 20 seconds with walk-away automation, addressing key laboratory pain points like short sample stability and manual labor. The company has achieved significant commercial traction, with its instruments used in over 60 countries and having delivered over 180 million patient results, positioning it as a high-growth player in the lab efficiency segment. ALCOR operates as a private, revenue-generating company with a clear focus on expanding its global distributor network and product portfolio.

Infectious DiseaseAutoimmune DisordersOncology

Technology Platform

Proprietary photometric rheology technology that measures red blood cell aggregation (rouleaux formation) to determine Erythrocyte Sedimentation Rate (ESR) in 20 seconds, replacing traditional gravity-based methods.

Funding History

4
Total raised:$11M
Series A$5M
Series A$3M
Seed$1.5M
Seed$1.5M

Opportunities

The primary opportunity lies in displacing manual Westergren and inferior automated ESR methods in labs worldwide, driven by the universal need for workflow efficiency and cost reduction.
The extended sample stability feature uniquely addresses modern lab logistics and testing delays.
The core photometric rheology platform could potentially be applied to automate other sedimentation-based or aggregation-based diagnostic tests, enabling portfolio expansion.

Risk Factors

Key risks include market reliance on a single test (ESR), facing competition from other automated ESR systems and alternative biomarkers, and the challenge of achieving universal adoption as the new standard method.
As a private company, scaling global operations and manufacturing to meet demand also presents execution risks.

Competitive Landscape

ALCOR competes in the automated ESR analyzer segment against other IVD manufacturers that offer alternatives to the manual Westergren method. Its primary competitive advantages are its 20-second result time, 7x longer sample stability, and full walk-away automation. It also competes indirectly, as ESR itself can be substituted by other inflammatory tests like CRP in some clinical protocols, though ESR offers unique diagnostic information.